In non-small-cell lung cancer (NSCLC), Engelman et al. [46] showed that cMET amplification could explain the resistance to EGFR tyrosine kinase inhibitors, such as gefitinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.